Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology

In the context of pancreatic cancer, surgical intervention is typically recommended for localized tumours, whereas chemotherapy is the preferred approach in the advanced and/or metastatic setting.

However, pancreatic cancer is closely linked to ageing, with an average diagnosis at 72 years.

Paradoxically, despite its increased occurrence among older individuals, this population is often underrepresented in clinical studies, complicating the decision-making process.

Age alone should not determine the therapeutic strategy but, given the high comorbidity and mortality of this disease, a comprehensive geriatric assessment (CGA) is necessary to define the best treatment, prevent toxicity, and optimize older patient care.

In this review, a group of experts from the Oncogeriatrics Section of the Spanish Society of Medical Oncology ( Sociedad Española de Oncología Médica , SEOM), the Spanish Cooperative Group for the Treatment of Digestive Tumours ( Grupo Español de Tratamiento de los Tumores Digestivos , TTD), and the Multidisciplinary Spanish Group of Digestive Cancer ( Grupo Español Multidisciplinar en Cáncer Digestivo , GEMCAD) have assessed the available scientific evidence and propose a series of recommendations on the management and treatment of the older population with pancreatic cancer.